Combination of Fludarabine and Imatinib Induces Apoptosis Synergistically Through Loss of Mitochondrial Membrane Potential and Increases in Caspase-3 Enzyme Activity in Human K562 Chronic Myleloid Leukemia Cells
| dc.contributor.author | Baran, Yusuf | |
| dc.contributor.author | Öztekin, Coşkun | |
| dc.contributor.author | Başsoy, Esen Yonca | |
| dc.coverage.doi | 10.3109/07357901003631056 | |
| dc.date.accessioned | 2017-01-05T12:36:30Z | |
| dc.date.available | 2017-01-05T12:36:30Z | |
| dc.date.issued | 2010 | |
| dc.description.abstract | In this study, we aimed to show the synergistic apoptotic effects of imatinib/fludarabine combination in human K562 chronic myleloid leukemia (CML) cells. There was a significant increase in cytotoxicity of combination of imatinib and fludarabine as compared to any agent alone. On the other hand, combination of both agents induced apoptosis significantly as confirmed by increases in caspase-3 enzyme activity and decreases in mitochondrial membrane potential. As a summary, the results of this study strongly suggest that combination of imatinib and fludarabine induced cell death synergistically comparing to only imatinib or fludarabine in human K562 CML cells. Copyright © 2010 Informa Healthcare USA, Inc. | en_US |
| dc.identifier.citation | Baran, Y., Öztekin, C., and Başsoy, E. Y. (2010). Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells. Cancer Investigation, 28(6), 623-628. doi:10.3109/07357901003631056 | en_US |
| dc.identifier.doi | 10.3109/07357901003631056 | en_US |
| dc.identifier.doi | 10.3109/07357901003631056 | |
| dc.identifier.issn | 0735-7907 | |
| dc.identifier.issn | 1532-4192 | |
| dc.identifier.scopus | 2-s2.0-77953182889 | |
| dc.identifier.uri | http://doi.org/10.3109/07357901003631056 | |
| dc.identifier.uri | https://hdl.handle.net/11147/2726 | |
| dc.language.iso | en | en_US |
| dc.publisher | Informa Healthcare | en_US |
| dc.relation.ispartof | Cancer Investigation | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Apoptosis | en_US |
| dc.subject | BCR/ABL | en_US |
| dc.subject | Chronic myeloid leukemia | en_US |
| dc.subject | Fludarabine | en_US |
| dc.subject | Imatinib | en_US |
| dc.title | Combination of Fludarabine and Imatinib Induces Apoptosis Synergistically Through Loss of Mitochondrial Membrane Potential and Increases in Caspase-3 Enzyme Activity in Human K562 Chronic Myleloid Leukemia Cells | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.institutional | Baran, Yusuf | |
| gdc.author.institutional | Başsoy, Esen Yonca | |
| gdc.author.yokid | 119193 | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Institute of Technology. Molecular Biology and Genetics | en_US |
| gdc.description.endpage | 628 | en_US |
| gdc.description.issue | 6 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q3 | |
| gdc.description.startpage | 623 | en_US |
| gdc.description.volume | 28 | en_US |
| gdc.description.wosquality | Q3 | |
| gdc.identifier.openalex | W2142789635 | |
| gdc.identifier.pmid | 20307198 | |
| gdc.identifier.wos | WOS:000278740000006 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.accesstype | BRONZE | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 2.0 | |
| gdc.oaire.influence | 2.9670755E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Apoptosis | |
| gdc.oaire.keywords | Piperazines | |
| gdc.oaire.keywords | Fludarabine | |
| gdc.oaire.keywords | Inhibitory Concentration 50 | |
| gdc.oaire.keywords | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | |
| gdc.oaire.keywords | Antineoplastic Combined Chemotherapy Protocols | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | BCR/ABL | |
| gdc.oaire.keywords | Cell Proliferation | |
| gdc.oaire.keywords | Membrane Potential, Mitochondrial | |
| gdc.oaire.keywords | Cell Death | |
| gdc.oaire.keywords | Dose-Response Relationship, Drug | |
| gdc.oaire.keywords | Caspase 3 | |
| gdc.oaire.keywords | Chronic myeloid leukemia | |
| gdc.oaire.keywords | Drug Synergism | |
| gdc.oaire.keywords | Mitochondria | |
| gdc.oaire.keywords | Pyrimidines | |
| gdc.oaire.keywords | Imatinib | |
| gdc.oaire.keywords | Benzamides | |
| gdc.oaire.keywords | Imatinib Mesylate | |
| gdc.oaire.keywords | K562 Cells | |
| gdc.oaire.keywords | Vidarabine | |
| gdc.oaire.popularity | 2.7302616E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.sciencefields | 0302 clinical medicine | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 0.36262943 | |
| gdc.openalex.normalizedpercentile | 0.61 | |
| gdc.opencitations.count | 7 | |
| gdc.plumx.crossrefcites | 4 | |
| gdc.plumx.mendeley | 11 | |
| gdc.plumx.pubmedcites | 1 | |
| gdc.plumx.scopuscites | 6 | |
| gdc.scopus.citedcount | 6 | |
| gdc.wos.citedcount | 6 | |
| relation.isAuthorOfPublication.latestForDiscovery | 7bb863bb-9384-4a07-9fbb-b9c1ab7634a3 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 9af2b05f-28ac-4013-8abe-a4dfe192da5e |